{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06215261",
            "orgStudyIdInfo": {
                "id": "TSND201-PTSD-202"
            },
            "organization": {
                "fullName": "Transcend Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD",
            "officialTitle": "An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD IMPACT-2 (Investigation of Methylone for Post-Traumatic Stress Disorder [PTSD])",
            "acronym": "IMPACT-2",
            "therapeuticArea": [
                "Other"
            ],
            "study": "an-evaluation-of-the-safety-and-efficacy-of-methylone-for-the-treatment-of-ptsd"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04-04",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-01-10",
            "studyFirstSubmitQcDate": "2024-01-10",
            "studyFirstPostDateStruct": {
                "date": "2024-01-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-11",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Transcend Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study is evaluating the safety and efficacy of methylone in adults with PTSD. The study is conducted in two parts.\n\n* Part A is open-label and will enroll up to 15 participants with PTSD\n* Part B is randomized (1:1), double-blind, placebo-controlled and will enroll up to 64 participants with PTSD\n\nEligible participants will enter a 3-week Treatment Period where they will receive methylone (or placebo in Part B) once weekly for 3 weeks (3 treatment sessions). Following the Treatment Period, participants will enter a 6-week Follow-up Period."
        },
        "conditionsModule": {
            "conditions": [
                "Post Traumatic Stress Disorder"
            ],
            "keywords": [
                "Methylone",
                "IMPACT-2",
                "PTSD",
                "Neuroplastogen"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 79,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Methylone",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Methylone"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Methylone",
                    "description": "Methylone capsules, given orally, once a week for 3 weeks",
                    "armGroupLabels": [
                        "Methylone"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Placebo capsules to match methylone, given orally, once a week for 3 weeks NOTE: Placebo is only in Part B",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change from Baseline in Clinician-Administered PTSD Scale for the DSM-5 (CAPS-5) total severity score",
                    "description": "The CAPS-5 is a structured interview designed to assess PTSD symptom severity. The total severity score ranges from 0 to 80, with a higher score indicating more severe symptoms.",
                    "timeFrame": "Up to 9 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score",
                    "description": "The MADRS is a 10-item, clinician-rated scale designed to assess severity of depression. The total score ranges from 0 to 60, with a higher score indicating more severe depression.",
                    "timeFrame": "Up to 9 weeks"
                },
                {
                    "measure": "Change from Baseline in PTSD Checklist for DSM-5 (PCL-5)",
                    "description": "The PCL-5 is a 20-item, patient-rated scale designed to measure severity of PTSD symptoms. The total score ranges from 0 to 80, with a higher score indicating more severe PTSD symptoms.",
                    "timeFrame": "Up to 9 weeks"
                },
                {
                    "measure": "Change from Baseline in Sheehan Disability Scale (SDS)",
                    "description": "The SDS is a 3-item, patient-rated scale designed to measure disability and impairment across three domains: work/school, social life, and family life/home responsibilities. Each domain is scored from 0 to 10, with higher scores representing greater disability. Total scores range from 0 to 30.",
                    "timeFrame": "Up to 9 weeks"
                },
                {
                    "measure": "Incidence of treatment-emergent adverse events (TEAEs)",
                    "description": "Types and rates of adverse events",
                    "timeFrame": "Up to 9 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Meets DSM-5 criteria for severe PTSD diagnosis, with a symptom duration of at least 6 months.\n* CAPS-5 score of at least 35 at Screening.\n* Failed at least one treatment for PTSD (either psychotherapy or pharmacological treatment).\n* Proficient in reading and writing in local language sufficient to complete questionnaires.\n* Free for any other clinically significant illness or disease.\n\nExclusion Criteria:\n\n* Primary diagnosis of any other DSM-5 disorder.\n* Body mass index (BMI) \\<18kg/m2 or \u226540 kg/m2.\n* Smokes an average of \\>10 cigarettes and/or e-cigarettes per day.\n* Uncontrolled hypertension at Screening.\n* Use of prohibited concomitant medications or therapies.\n* Current or previous history of clinically significant cardiovascular/cerebrovascular conditions.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "70 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Study Director",
                    "role": "CONTACT",
                    "phone": "+1 (650) 382-2719",
                    "email": "alyssa@transcendtherapeutics.com"
                }
            ],
            "locations": [
                {
                    "facility": "Segal Trials",
                    "status": "RECRUITING",
                    "city": "Lauderhill",
                    "state": "Florida",
                    "zip": "33319",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Simran Juneja",
                            "role": "CONTACT",
                            "email": "sjuneja@segaltrials.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 26.14036,
                        "lon": -80.21338
                    }
                },
                {
                    "facility": "CNS Healthcare",
                    "status": "RECRUITING",
                    "city": "Orlando",
                    "state": "Florida",
                    "zip": "32801",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ashley Westerfeld",
                            "role": "CONTACT",
                            "email": "awesterfeld@cnshealthcare.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.53834,
                        "lon": -81.37924
                    }
                },
                {
                    "facility": "Uptown Clinical Research",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60640",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Stephen Schneider",
                            "role": "CONTACT",
                            "email": "sschneider@uptownresearch.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                },
                {
                    "facility": "Swinburne University of Technology",
                    "status": "RECRUITING",
                    "city": "Hawthorn",
                    "state": "Victoria",
                    "zip": "3122",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Martin Williams",
                            "role": "CONTACT",
                            "email": "martinwilliams@swin.edu.au"
                        }
                    ],
                    "geoPoint": {
                        "lat": -34.97384,
                        "lon": 138.60738
                    }
                },
                {
                    "facility": "Ramsay Clinic Albert Road",
                    "status": "RECRUITING",
                    "city": "Melbourne",
                    "state": "Victoria",
                    "zip": "3004",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "email": "research.arc@ramsayhealth.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": -37.814,
                        "lon": 144.96332
                    }
                },
                {
                    "facility": "Monarch Mental Health Group",
                    "status": "RECRUITING",
                    "city": "Melbourne",
                    "state": "Victoria",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Bernadette Fitzgibbon",
                            "role": "CONTACT",
                            "email": "bfitzgibbon@mmhg.com.au"
                        }
                    ],
                    "geoPoint": {
                        "lat": -37.814,
                        "lon": 144.96332
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000040921",
                    "term": "Stress Disorders, Traumatic"
                },
                {
                    "id": "D000013313",
                    "term": "Stress Disorders, Post-Traumatic"
                }
            ],
            "ancestors": [
                {
                    "id": "D000068099",
                    "term": "Trauma and Stressor Related Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M24916",
                    "name": "Stress Disorders, Traumatic",
                    "asFound": "Traumatic Stress Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M16103",
                    "name": "Stress Disorders, Post-Traumatic",
                    "asFound": "Post Traumatic Stress Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17685",
                    "name": "Wounds and Injuries",
                    "relevance": "LOW"
                },
                {
                    "id": "M222",
                    "name": "Trauma and Stressor Related Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC26",
                    "name": "Wounds and Injuries"
                }
            ]
        }
    },
    "hasResults": false
}